Alnylam Pharmaceuticals
ALNY
#663
Rank
ยฃ24.07 B
Marketcap
ยฃ186.65
Share price
-8.67%
Change (1 day)
37.14%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : ยฃ3.30 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are ยฃ3.30 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31ยฃ3.17 B3.83%
2022-12-31ยฃ3.06 B35.29%
2021-12-31ยฃ2.26 B29.04%
2020-12-31ยฃ1.75 B140.48%
2019-12-31ยฃ0.72 B239.34%
2018-12-31ยฃ0.21 B27.24%
2017-12-31ยฃ0.16 B-39.16%
2016-12-31ยฃ0.27 B237.82%
2015-12-31ยฃ82.18 M-10.72%
2014-12-31ยฃ92.05 M1.11%
2013-12-31ยฃ91.04 M-4.11%
2012-12-31ยฃ94.95 M-9.97%
2011-12-31ยฃ0.10 B-30.73%
2010-12-31ยฃ0.15 B-18.8%
2009-12-31ยฃ0.18 B-22.05%
2008-12-31ยฃ0.24 B62.2%
2007-12-31ยฃ0.14 B648.07%
2006-12-31ยฃ19.82 M-6.51%
2005-12-31ยฃ21.2 M103.91%
2004-12-31ยฃ10.39 M-69.94%
2003-12-31ยฃ34.59 M167.26%
2002-12-31ยฃ12.94 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
ยฃ0.43 B-86.94%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ6.43 B 94.50%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.88 B-42.99%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.46 B-85.99%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ4.7 M-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ47.60 B 1,339.91%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ48.21 B 1,358.14%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ28.02 B 747.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel